Preimplantation Genetic Testing Market Size & Share, by Technology (Next-Generation Sequencing, Polymerase Chain Reaction); Application (HLA Typing, Aneuploidy Screening, IVF Prognosis); Procedure Type (Preimplantation Genetic Diagnosis, Preimplantation Genetic Screening); Products & Services (Instruments, Reagents & Consumables, Software & Services) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4793
  • Published Date: Apr 06, 2023
  • Report Format: PDF, PPT

Companies Dominating the Preimplantation Genetic Testing Landscape

top-features-companies
    • Illumina, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • PerkinElmer LSDX
    • Abbott
    • Natera, Inc.
    • Yikon Genomics
    • Invitae Corporation
    • Genea Energy Partners Inc.
    • Eurofins Genoma Germany GmbH
    • Genomic Prediction

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Eurofins Genoma launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. Preimplantation genetic testing for aneuploidy (PGT-A) enables medical professionals to determine the chromosomal makeup of in vitro fertilized (IVF) embryos

  • LifeView powered by Genomic Prediction announces the partnership of Ovation Fertility with Genomic Prediction to approve the license for the LIfeView PGT Platform for genetic testing. Through this partnership, Ovation patients will have access to cutting-edge technologies and better clinical care.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4793
  • Published Date: Apr 06, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cases of congenital disorders, rising prevalence of genetic deformity, and increasing popularity of in-vitro fertilization are the major factors driving the market growth.

The market size of preimplantation genetic testing is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2023-2035.

Ethical concerns regarding the unnatural procedures, and the lack of professional physicians are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer LSDX, Abbott, Natera, Inc., Yikon Genomics,, Invitae Corporation, Genea Energy Partners, Inc., Eurfons Genoma Germany GmbH, and Genomic Prediction.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by technology, application, procedure type, products & services, end user, and by region.

The preimplantation genetic diagnosis segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying